MannKind Corp. (MNKD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.94-5.29%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Improve earnings per share to positive territory: EPS -6.0% vs 9.0% target.
MannKind aims to grow revenue to $349 million in 2026. The company has formed a strategic partnership and completed an acquisition to strengthen its pipeline. Analysts expect revenue to rise about 28% next year. Profitability is improving from prior losses.
Revenue declined from $111.96 million in Q4 2025 to $90.17 million in Q1 2026. The company has missed earnings estimates multiple times recently. High valuation multiples and ongoing losses raise risk. Growth targets may be too optimistic given current trends.
The stock price is about 24% below our valuation midpoint and 38% below the median analyst target. The market expects roughly 28% revenue growth next year. Our view aligns with moderate growth but remains cautious on profitability and execution risks.
Breaks if: EPS remains negative or below $0.05 in FY26
Breaks if: annual revenue falls below $300 million in FY26
Partnerships or acquisitions fail to contribute or cause operational disruption
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a healthcare company with a focus on expanding its commercial portfolio and advancing clinical programs. The current thesis state is intact, supported by robust earnings quality and strong recent financial performance, despite some mixed signals.
The market appears to have priced in a low expectations gap, indicating that MNKD is seen as cheap compared to its peers. However, the valuation reflects a justified stance, as the company is currently loss-making and navigating a challenging environment.
Management is making progress on its priorities, with revenue growth and clinical advancements on track. However, there is a near-term risk of missing earnings expectations, which could impact sentiment.
The thesis hinges on management's ability to meet revenue guidance and successfully navigate the healthcare sector's performance. Key factors include potential earnings guidance cuts and the performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company exceeded its revenue forecast for Q2 2026, supporting its 2026 guidance of $349 million. However, the latest earnings report showed a miss, which poses a threat to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, MNKD's performance will depend on its execution against growth targets and external market conditions. Not investment advice.